Document is current

Article History

Received: 21 July 2020

Accepted: 23 October 2020

First Online: 25 November 2020

Competing interests

: J.LL. and J.M. are employees of Laboratorios Farmacéuticos Rovi, S.A., the sole developer of Risperidone ISM^®. CU.C. has been a consultant and/or advisor to or have received honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, Laboratorios Farmacéuticos Rovi, S.A, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. RE.L., is a Member, Speakers Bureau, for JNJ and for Allergan, Member, Scientific Advisory Board, Terran BioSciences. He participated as Investigator Coordinator in The United States of America and as Principal Investigator in the study PRISMA-3. Y.F. has participated as Investigator Coordinator in Ukraine and Principal Investigator in the study PRISMA-3. He received fees from the sponsor for his advice in some previous task related to this study. D.N., has received consulting fees from Laboratorios Farmacéuticos Rovi, S.A. He served on the Data Monitoring Committee for Rovi at the present study. F.T. has received consulting fees from Laboratorios Farmacéuticos Rovi, S.A. He served on the Data Monitoring Committee for Rovi at the present study.